Header Logo

Connection

Debra Richardson to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Debra Richardson has written about Antibodies, Monoclonal, Humanized.
Debra Richardson
Connection Strength
0.387
Antibodies, Monoclonal, Humanized
  1. Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor). BMC Cancer. 2025 Mar 18; 25(1):500.
    View in: PubMed
    Score: 0.218
  2. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2008 Dec; 111(3):461-6.
    View in: PubMed
    Score: 0.070
  3. Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer. J Immunother Cancer. 2025 Mar 13; 13(3).
    View in: PubMed
    Score: 0.054
  4. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? Int J Gynecol Cancer. 2013 Jun; 23(5):833-8.
    View in: PubMed
    Score: 0.024
  5. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol. 2011 May 01; 121(2):269-72.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.